
浏览全部资源
扫码关注微信
1.西安市中心医院药剂科,西安 710003
2.西安市第一医院药剂科,西安 710002
主管药师,硕士。研究方向:医院药物警戒。E-mail:baihehe2010@163.com
主管药师。研究方向:医院药学。E-mail:519925564@qq.com
收稿日期:2023-12-01,
修回日期:2024-03-15,
录用日期:2024-03-22,
纸质出版日期:2024-04-30
移动端阅览
白荷荷,彭莉蓉,王园姬,等.头孢哌酮/舒巴坦致血小板减少列线图预测模型的建立与验证[J].中国药房,2024,35(08):980-985.
BAI Hehe,PENG Lirong,WANG Yuanji,et al.Establishment and validation of nomogram prediction model of cefoperazone/sulbactam-induced thrombocytopenia[J].ZHONGGUO YAOFANG,2024,35(08):980-985.
白荷荷,彭莉蓉,王园姬,等.头孢哌酮/舒巴坦致血小板减少列线图预测模型的建立与验证[J].中国药房,2024,35(08):980-985. DOI: 10.6039/j.issn.1001-0408.2024.08.14.
BAI Hehe,PENG Lirong,WANG Yuanji,et al.Establishment and validation of nomogram prediction model of cefoperazone/sulbactam-induced thrombocytopenia[J].ZHONGGUO YAOFANG,2024,35(08):980-985. DOI: 10.6039/j.issn.1001-0408.2024.08.14.
目的
2
探讨头孢哌酮/舒巴坦致成人住院患者血小板减少的预测因子,建立列线图预测模型并进行验证。
方法
2
回顾性收集西安市中心医院2021年6月30日至2023年6月30日使用头孢哌酮/舒巴坦治疗的成人住院患者资料,按7∶3随机分为训练集和内部验证集。采用单因素/多因素Logistic回归分析筛选头孢哌酮/舒巴坦致血小板减少的独立预测因子,通过R 4.0.3软件“RMS”包绘制列线图;采用受试者工作特征曲线及C-index值评估模型的预测效能;采用Hosmer-Lemeshow拟合优度检验评价模型的校正度。以相同标准,收集西安市第一医院同期使用头孢哌酮/舒巴坦治疗的成人住院患者的临床资料,对列线图预测模型进行外部验证。
结果
2
共纳入西安市中心医院患者1 045例,其中头孢哌酮/舒巴坦致血小板减少患者67例,发生率为6.41%。排除假阳性患者后,最终纳入患者473例,其中训练集331例、内部验证集142例。多因素Logistic回归分析结果显示,患者年龄[OR=1.043,95%CI(1.017,1.070)
]
、估算的肾小球滤过率(eGFR)[OR=0.988,95%CI(0.977,0.998)
]
、基线血小板[OR=0.989,95%CI(0.982,0.996)
]
、营养风险[OR=3.863,95%CI(1.884,7.921)
]
和累计限定日剂量数(DDDs)[OR=1.082,95%CI(1.020,1.147)
]
是头孢哌酮/舒巴坦致血小板减少的独立预测因子(
P
<0.05)。训练集和内部验证集的C-index值分别为0.824[95%CI(0.759,0.890)
]
和0.828[95%CI(0.749,0.933)
]
,Hosmer-Lemeshow检验的
χ
2
值分别为0.441、1.804(
P
值分别为0.802、0.406)。外部验证集中,C-index值为0.808[95%CI(0.672,0.945)
]
,Hosmer-Lemeshow检验的
χ
2
值为0.899(
P
值为0.638)。
结论
2
患者年龄、基线血小板、eGFR、营养风险和累计DDDs是头孢哌酮/舒巴坦致血小板减少的独立预测因子;所建列线图预测模型具有良好的预测效能和外推性,有助于临床快速、准确地识别头孢哌酮/舒巴坦致血小板减少的潜在风险。
OBJECTIVE
2
To explore the predictive factors of cefoperazone/sulbactam-induced thrombocytopenia in adult inpatients, and to establish and validate the nomogram prediction model.
METHODS
2
Data of adult inpatients treated with cefoperazone/sulbactam in Xi’an Central Hospital from Jun. 30th, 2021 to Jun. 30th, 2023 were retrospectively collected. The training set and internal validation set were randomly constructed in a 7∶3 ratio. Singler factor and multifactor Logistic regression analysis were used to screen the independent predictors of cefoperazone/sulbactam-induced thrombocytopenia. The nomogram was drawn by using “RMS” of R 4.0.3 software, and the predictive performance of the model was evaluated by the receiver operating characteristic curve and C-index curve. Hosmer-Lemeshow goodness-of-fit test was used to evaluate the calibration degree of the model. Using the same standard, the clinical data of hospitalized patients receiving cefoperazone/sulbactam in Xi’an First Hospital in the same period were collected for external validation of the nomogram prediction model.
RESULTS
2
A total of 1 045 patients in Xi’an Central Hospital were included in this study, among which 67 patients suffered from cefoperazone/sulbactam-induced thrombocytopenia, with an incidence of 6.41%. After the false positive patients were excluded, 473 patients were included finally, including 331 in the training set and 142 in the internal validation set. Multifactor Logistic regression analysis showed that age [OR=1.043, 95%CI(1.017, 1.070)
]
, estimated glomerular filtration rate (eGFR)[OR=0.988, 95%CI(0.977, 0.998)
]
, baseline platelet (PLT) [OR=0.989, 95%CI(0.982, 0.996)
]
, nutritional risk [OR=3.863, 95%CI(1.884, 7.921)
]
and cumulative defined daily doses (DDDs) [OR=1.082, 95%CI(1.020, 1.147)
]
were independent predictors for cefoperazone/sulbactam-induced thrombocytopenia (
P
<0.05). The C-index values of the training set and the internal validation set were 0.824 [95%CI (0.759, 0.890)
]
and 0.828 [95%CI (0.749, 0.933)
]
, respectively. The results of the Hosmer-Lemeshow test showed that
χ
2
values were 0.441 (
P
=0.802) and 1.804 (
P
=0.406). In the external validation set, the C-index value was 0.808 [95%CI (0.672, 0.945)
]
, the
χ
2
value of the Hosmer-Lemeshow test was 0.899 (
P
=0.638).
CONCLUSIONS
2
The independent predictors of cefoperazone/sulbactam-induced thrombocytopenia include age, baseline PLT, eGFR, nutritional risk and cumulative DDDs. The model has good predictive efficacy and extrapolation ability, which can help clinic identify the potential risk of cefoperazone/sulbactam-induced thrombocytopenia quickly and accurately.
KU Y H , YU W L . Cefoperazone/sulbactam:new compo-sites against multiresistant Gram-negative bacteria? [J ] . Infect Genet Evol , 2021 , 88 : 104707 .
SADER H S , CARVALHAES C G , STREIT J M , et al . Antimicrobial activity of cefoperazone-sulbactam tested against Gram-negative organisms from Europe,Asia-Pacific,and Latin America [J ] . Int J Infect Dis , 2020 , 91 : 32 - 37 .
OVSIANKIN A V , MUKONIN A A . Clinical and bacteriological substantiation of the use of cefoperazone/sulbactam in complex therapy of patients with pyo-destructive forms of lower respiratory tract infection(LRTI) [J ] . Antibiot Chemotherapy Sic , 2004 , 49 ( 6 ): 25 - 29 .
栗啸阳 , 郭代红 , 刘思源 , 等 . 注射用头孢哌酮钠舒巴坦钠相关血小板减少的自动监测研究 [J ] . 中国药物警戒 , 2020 , 17 ( 12 ): 890 - 893,903 .
LI X Y , GUO D H , LIU S Y , et al . Automatic surveillance of cases of cefoperazone sodium and sulbactam sodium-related thrombocytopenia [J ] . Chin J Pharmacovigil , 2020 , 17 ( 12 ): 890 - 893,903 .
郭晓明 , 王莹 , 刘娜 , 等 . 头孢哌酮钠舒巴坦钠致血小板减少症的危险因素分析 [J ] . 中国医院用药评价与分析 , 2021 , 21 ( 10 ): 1273 - 1276,1280 .
GUO X M , WANG Y , LIU N , et al . Analysis of risk factors for thrombocytopenia induced by cefoperazone sodium and sulbactam sodium [J ] . Eval Anal Drug Use Hosp China , 2021 , 21 ( 10 ): 1273 - 1276,1280 .
武东 , 汪晓娟 , 汪小五 , 等 . 104例住院患者药源性血小板减少症不良反应报告分析 [J ] . 中国医院药学杂志 , 2019 , 39 ( 17 ): 1766 - 1771 .
WU D , WANG X J , WANG X W , et al . Analysis of 104 cases of adverse reaction of drug-induced thrombocyto-penia in hospitalized patients [J ] . Chin J Hosp Pharm , 2019 , 39 ( 17 ): 1766 - 1771 .
米文娟 , 唐中权 . 头孢菌素致药源性血小板减少症35例的文献分析 [J ] . 国外医药(抗生素分册) , 2021 , 42 ( 2 ): 77 - 81 .
MI W J , TANG Z Q . Comprehensive analysis on drug-induced thrombocytopenia of 35 cases with cephalosporin [J ] . World Notes Antibiot , 2021 , 42 ( 2 ): 77 - 81 .
BAI H H , LI H , NIE X J , et al . Development and vali-dation of a nomogram for predicting cefoperazone/sulbactam-induced hypoprothrombinaemia in hospitalized adult patients [J ] . PLoS One , 2023 , 18 ( 9 ): e0291658 .
HAN X N , WANG J P , ZAN X , et al . Risk factors for linezolid-induced thrombocytopenia in adult inpatients [J ] . Int J Clin Pharm , 2022 , 44 ( 2 ): 330 - 338 .
王钰莹 , 于建海 , 段京莉 . 头孢哌酮舒巴坦引起凝血功能异常的影响因素分析研究 [J ] . 中国全科医学 , 2020 , 23 ( 增刊1 ): 138 - 140 .
WANG Y Y , YU J H , DUAN J L . Analysis of influencing factors of coagulation dysfunction caused by cefoperazone and sulbactam [J ] . Chin Gen Pract , 2020 , 23 ( Suppl. 1 ): 138 - 140 .
李静 , 王卓亚 . 血小板与衰老相关疾病的研究进展 [J ] . 临床医学进展 , 2022 , 12 ( 10 ): 9132 - 9139 .
LI J , WANG Z Y . Research progress on platelet and aging-related diseases [J ] . Advan Clin Med , 2022 , 12 ( 10 ): 9132 - 9139 .
WANG W , LIU Y M , YU C , et al . Cefoperazone-sulbactam and risk of coagulation disorders or bleeding:a retrospective cohort study [J ] . Expert Opin Drug Saf , 2020 , 19 ( 3 ): 339 - 347 .
PAGE M J , PRETORIUS E . A champion of host defense:a generic large-scale cause for platelet dysfunction and depletion in infection [J ] . Semin Thromb Hemost , 2020 , 46 ( 3 ): 302 - 319 .
SCHENTAG J J , WELAGE L S , GRASELA T H , et al . Determinants of antibiotic-associated hypoprothrom-binemia [J ] . Pharmacotherapy , 1987 , 7 ( 3 ): 80 - 86 .
WONG R S , CHENG G , CHAN N P , et al . Use of cefoperazone still needs a caution for bleeding from induced vitamin K deficiency [J ] . Am J Hematol , 2006 , 81 ( 1 ): 76 .
STROM B L , SCHINNAR R , GIBSON G A , et al . Risk of bleeding and hypoprothrombinaemia associated with NMTT side chain antibiotics:using cefoperazone as a test case [J ] . Pharmacoepidemiol Drug Saf , 1999 , 8 ( 2 ): 81 - 94 .
0
浏览量
31
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
公网安备50010302001817